SPECT Biomarker Ctte: Difference between revisions
Jump to navigation
Jump to search
| Line 22: | Line 22: | ||
==Reference Materials== | ==Reference Materials== | ||
*[[Media:Acquisition Process.pdf | Acquisition Processes for SPECT - Drs. Dewaraja, Frey, and Iida (notes)]] ''December 8, 2015'' | |||
*[[Media:System Variance Model for SPECT Ioflupane.pdf | System Variance Model for SPECT Ioflupane - Drs. Smith and Zeintl (Siemens)]] ''November 20, 2015'' | *[[Media:System Variance Model for SPECT Ioflupane.pdf | System Variance Model for SPECT Ioflupane - Drs. Smith and Zeintl (Siemens)]] ''November 20, 2015'' | ||
Revision as of 16:36, 10 December 2015
Project Snapshot
The SPECT Biomarker Committee seeks to develop a quantitative imaging profile for SPECT imaging.
Under consideration:
- quantifying a small structure (like the basal ganglion in the DaTscan, thyroid)
- quantifying organs, like the liver, for dosimetry as potential use cases
Meetings/Call Summaries
Working Documents
Statistical Reference Documents
Workflow Documents
Reference Materials
- QIBA Claim Statement Types - Dr. Obuchowski November 20, 2015
- 03.20.2015 Link to papers of the group in Umeå that are collaborating with Dr. Ljungberg:
- The PI for this is Anne Larsson, PhD: http://www.ncbi.nlm.nih.gov/pubmed/?term=dat+scan+Larsson+A